Ed Biotech (300685): Net profit deducted from non-return to mother increased 26% year-on-year in the first quarter, consolidating the leading position in the industry
Ed Biotech (300685): Domestic share is expected to increase and accelerate overseas market development
Ed Biotech (300685): Leading companies in the regulatory development and compliance of the oncology genetic testing industry benefit from many parties
Ed Biotech (300685): First quarter results are in line with expectations, optimistic about the release of innovative products
Ed Biotech (300685): Performance has achieved steady growth, and the new product layout is expected to accelerate
Guoxin Securities released a research report on April 23 stating that it gave Ed Biotech (300685.SZ) a purchase rating. The main reasons for the rating include: 1) revenue surpassed 1 billion dollars for the first time, and the leading position in the hos
Ed Biotech (300685): Revenue increased 38% year-on-year in the fourth quarter, and insisted on using the hospital market as the main track
Ed Biotech (300685): Performance is in line with expectations, and compliance advantages are highlighted
Ed Biotech (300685): Annual results exceeded expectations and accelerated development of domestic and foreign markets
Ed Biotech (300685): Contrary to the trend, the performance exceeded expectations
Ed Biotech (300685): Net profit to mother increased 108% year-on-year in the fourth quarter, bucking the trend, demonstrating leading position
Ed Biotech (300685) 2023 Third Quarter Report Review: Revenue Growth, Steady Equity Incentives Show Confidence
Ed Biotech (300685): Revenue increased 20% year-on-year in the single third quarter and continued to increase investment in R&D
Ed Biotech (300685): Performance is in line with expectations and continues to further research and development
Ed Biotech (300685): Revenue met expectations, net profit was slightly lower than expected, and in-hospital reagent sales gradually recovered
Ed Biotech (300685) 2023 Third Quarter Report Review: Revenue is Growing Steady and Cooperation with Pharmaceutical Companies Continues to Deepen
Ed Biotech (300685): Steady revenue growth, exchange and R&D investment drag down profits
Ed Biotech (300685) Company Review: Pharmaceutical Company Cooperation Enhances New Product Launch
Ed Biotech (300685): The launch of a high-throughput gene sequencer with broad equity incentive coverage was approved
Ed Biotech (300685): A New Round of Equity Incentives Shows Confidence
No Data